Russian invasion of Ukraine could impact over 200 clinical studies

Many biotech and pharmaceutical companies have ongoing clinical trials in Ukraine, and the war in the country could delay drug development.

The war in Ukraine has already had consequences for the local population. Depicted is a building in capital Kyiv that has been destroyed by a Russian missile | Photo: UMIT BEKTAS/REUTERS / X90076

The war in Ukraine is undoubtedly affecting many people’s lives, and many have already abandoned their homes as Russian troops edge closer to the country’s capital, Kyiv.

Biotech and pharmaceutical firms operating in Ukraine will also be impacted, reports industry media Fierce Pharma.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs